Prospective assessment of tizanidine for spasticity due to acquired brain injury

Archives of Physical Medicine and Rehabilitation

Volumn 82, Issue 9, 2001, Pages 1155-1163

  Meythaler, Jay M ^a   Guin Renfroe, Sharon ^a   Johnson, Alice ^a   Brunner, Robert M ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Baclofen; Brain injuries; Cerebral palsy; Cerebrovascular accident; Dystonia; Muscle hypertonia; Muscle spasticity; Rehabilitation

Indexed keywords

TIZANIDINE;

ADULT; AGED; ARTICLE; BRAIN INJURY; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; EDEMA; FEMALE; HUMAN; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MICTURITION DISORDER; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; MUSCLE RIGIDITY; MUSCLE SPASM; MUSCLE STRENGTH; MUSCLE TONE; MYASTHENIA; PAIN; RANDOMIZED CONTROLLED TRIAL; SPASTICITY; STROKE; TENDON REFLEX; UNIVERSITY HOSPITAL; XEROSTOMIA;

EID: 0034853389     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1053/apmr.2001.25141     Document Type: Article

References (42)

1. Drug therapy: Spasticity (first of two parts)
2. Drug therapy: Spasticity (second of two parts)
3. Management of spasticity
4. Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: A preliminary report
5. Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-Year experience
6. Time course of muscle atrophy and recovery following a phenol-induced nerve block
7. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury
8. Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebo-controlled trial
9. Continuous intrathecal baclofen infusion for spasticity of cerebral origin
10. The Ashworth scale: A reliable and reproducible method of measuring spasticity
11. Preliminary trial of carisoprodol in multiple sclerosis
12. Intrathecal baclofen for severe spinal spasticity
13. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury
14. Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study
15. Relationship between impairment and physical disability as measured by the functional independence measure
16. Quantifying handicap: A new measure of long-term rehabilitation outcomes
17. A major complication of craniocerebral trauma
18. Rehabilitation of the patient with traumatic brain injury
19. Segmental reflex pathways in spinal shock and spinal spasticity in man
20. Tizanidine: Neuropharmacology and mechanism of action Neurology
21. Tizanidine and electrophysiologic analysis of spinal control mechanisms in humans with spasticity
22. Functional management of spasticity after head injury
23. Pharmacology update: Intrathecal baclofen for spastic hypertonia in brain injury
24. Continuous intrathecal baclofen for symptomatic generalized dystonia
25. Use of intrathecal baclofen in the treatment of patients with dystonia
26. Clonidine effect on spasticity: A clinical trial
27. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments
28. Comparison of alpha-adrenoceptor involvement in the antinociceptive action of tizanidine and clonidine in the mouse
29. Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord
30. Pharmacokinetics and pharmacodynamics of tizanidine
31. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia
32. A double-blind, long term study of tizanidine (’Sirdalud’) in spasticity due to cerebrovascular lesions
33. Flexor reflex for assessment of common interneurone activity in spasticity
34. Mechanisms of tizanidine action on spasticity
35. Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke
36. Comparative profile of tizanidine in the management of spasticity
37. Tizanidine in cranial dystonia
38. The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiadiazole (DS 103-282), a novel myotonolytic agent
39. Pharmacologic modulation of recovery after stroke: Clinical data